DrugDashboards

Methylprednisolone Sodium Succinate

Methylprednisolone Sodium Succinate · METHYLPREDNISOLONE SODIUM SUCCINATE 500 mg/1 · Injection, Powder, Lyophilized, For Solution · Intramuscular; Intravenous · Eugia US LLC

NDC 55150-0264-20 · 1 VIAL, MULTI-DOSE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for methylprednisolone sodium succinate (injectable) in the next 90 days

sterile injectable · sole-source market · price up 4% YoY

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA207667
TE code
—
Approval date
Dec 15, 2015
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Methylprednisolone Sodium Succinate (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Eugia US LLCMETHYLPREDNISOLONE SODIUM SUCCINATE 2 g/1Jul 15, 2026Sep 2, 2026
Eugia US LLCMETHYLPREDNISOLONE SODIUM SUCCINATE 125 mg/1Jul 15, 2026Sep 2, 2026
Eugia US LLCMETHYLPREDNISOLONE SODIUM SUCCINATE 40 mg/1Jul 15, 2026Sep 2, 2026
Eugia US LLCMETHYLPREDNISOLONE SODIUM SUCCINATE 500 mg/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCMETHYLPREDNISOLONE SODIUM SUCCINATE 40 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCMETHYLPREDNISOLONE SODIUM SUCCINATE 125 mg/2mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCMETHYLPREDNISOLONE SODIUM SUCCINATE 1 g/16mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Methylprednisolone Sodium Succinate — NDC 55150-0264-20," retrieved September 3, 2026, https://drugdashboards.com/drug/55150026420.

Free to cite with attribution — see how the data is put together.